Business, energy, technology, markets and global industry news from Business News Today

TREMFYA

PharmaDeviceNews TREMFYA
Pharma & Biotech

Can Johnson & Johnson’s oral Icotyde compete with biologics in psoriatic arthritis?

Icotyde achieved 58% ACR20 in Phase 3 psoriatic arthritis, but the 400 mg dose added no benefit. Can Johnson & Johnson challenge biologics?

Read More
Psoriasis treatment innovation moves closer to market as the US Food and Drug Administration grants Priority Review to Takeda’s zasocitinib following positive Phase 3 trial results, including head-to-head superiority over deucravacitinib in plaque psoriasis. Representative image.
Pharma & Biotech

Johnson & Johnson reports long-term ICOTYDE efficacy and safety in plaque psoriasis

Johnson & Johnson reports two-year ICOTYDE psoriasis results, with over 72% achieving PASI 90. See what the data mean for treatment.

Read More
Representative image showing a clinician reviewing joint health with a patient, reflecting Johnson & Johnson’s Tremfya FDA label expansion for structural joint damage inhibition in active psoriatic arthritis.
Pharma & Biotech

Can Tremfya turn radiographic evidence into a commercial advantage for Johnson & Johnson?

Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.

Read More
Pharma & Biotech

Why Johnson & Johnson’s May 19 RBC fireside chat matters more than it first appears

Johnson & Johnson will join RBC Healthcare 2026 on May 19. Read why investors will watch the fireside chat for growth, guidance, and risk signals.

Read More
Johnson & Johnson strengthens its ulcerative colitis position with extended guselkumab outcomes
Pharma & Biotech

Johnson & Johnson’s three-year TREMFYA data sharpen the durability debate in ulcerative colitis care

Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.

Read More